All In Biotech

BLA 125319 · Novartis Pharms

Ilaris

Canakinumab · Subcutaneous

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Nov 1, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Jun 17, 2009

Approved uses

8

Original approval plus efficacy supplements

Registered trials

106

36 Phase 3, 8 recruiting

FAERS reports

10,910

5,167 serious, 489 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 8, 2026.

ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 ) 1.1 Periodic Fever Syndromes ILARIS ® (canakinumab) is an interleukin-1β (IL-1β) blocker indicated for the treatment of the following autoinflammatory Periodic Fever Syndromes: Cryopyrin-Associated Periodic Syndromes (CAPS) ILARIS is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and pediatric patients 4 years of age and older, including: Familial Cold Autoinflammatory Syndrome (FCAS) Muckle-Wells Syndrome (MWS) Tumor Necrosis Factor Receptor (TNF) Associated Periodic Syndrome (TRAPS) ILARIS is indicated for the treatment of Tumor Necrosis Factor (TNF) Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients. Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) ILARIS is indicated for the treatment of...

Mechanism: Canakinumab is a human monoclonal anti-human IL-1β antibody of the IgG1/κ isotype. Canakinumab binds to human IL-1β and neutralizes its activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1α or IL-1 receptor antagonist (IL-1ra). CAPS refer to rare genetic syndromes generally caused by mutations in the NLRP-3 [nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Autoinflammatory Syndrome-1 [CIAS1]). CAPS disorders are inherited in an autosomal dominant pattern with male and female offspring equally...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 25, 2023 Supplement 107 · Efficacy LetterLabel
  • Jun 16, 2020 Supplement 97 · Efficacy · priority review OrphanLetterLabel
  • Sep 23, 2016 Supplement 85 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
  • Sep 23, 2016 Supplement 86 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
  • Sep 23, 2016 Supplement 87 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
  • Jul 21, 2016 Supplement 84 · Efficacy OrphanLabelLetter
  • May 9, 2013 Supplement 62 · Efficacy · priority review OrphanLabelLetter
  • Jun 17, 2009 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewSummary ReviewLabel
1 products under this application
  • ILARIS · CANAKINUMAB 180MG · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Canakinumab" as an intervention, any sponsor and status, largest first.

All 106 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia1,442
  • drug ineffective1,242
  • inappropriate schedule of drug administration1,242
  • inappropriate schedule of product administration966
  • pain946
  • condition aggravated876
  • off label use751
  • malaise731
  • arthralgia613
  • rash571
  • incorrect dose administered506
  • joint swelling492

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20109
201161
2012188
201398
2014143
2015493
2016956
20171,421
20181,130
2019985
20201,206
2021734
20221,021
2023972
2024632
2025521
2026339

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ilaris (Canakinumab/PF)

2024 spending

$55.7M

Beneficiaries

379

1,975 claims

Per beneficiary

$147,058

$18,603.17 per unit

View as table
YearSpending
2020$17,711,823
2021$25,811,119
2022$33,488,914
2023$39,279,713
2024$55,735,087

Part B: Ilaris (Canakinumab/PF) · HCPCS J0638

2024 spending

$21.4M

Beneficiaries

225

902 claims

Per beneficiary

$95,067

2024 ASP limit $125.79 per unit

View as table
YearSpending
2020$2,385,523
2021$4,056,681
2022$7,130,946
2023$12,350,189
2024$21,390,124

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 163 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.